Xianqiang Pharmaceutical

Guangdong Xianqiang Pharmaceutical Co., Ltd. is a high-tech biomedical enterprise and a wholly-owned subsidiary of Guangdong Zhong Sheng Pharmaceutical Co., Ltd. (stock code: 002317). It primarily engages in the research, development, production, and sales of chemical pharmaceuticals. The company was founded in 2002 with a registered capital of RMB 223.9 million. Currently, it has two subsidiaries: Guangdong Hongqiang Pharmaceutical Sales Co., Ltd. and Shanhaifeng (International) Trading Co., Ltd., and one branch: Guangdong Xianqiang Pharmaceutical Co., Ltd. Zhaoqing Branch.
After nearly two decades of development, the company has weathered the difficult initial stages of entrepreneurship and passed through the phases of growth and maturity. With the attention and support of governments at all levels and all sectors of society, the company has been recognized as a strategic emerging industry cultivation enterprise in Guangdong Province, a high-growth private enterprise in Guangdong Province, an innovative pilot enterprise in Guangzhou, a demonstration platform enterprise for service-oriented manufacturing in the Pearl River Delta region, and an A-level taxpayer of Guangzhou. It is a small and medium-sized enterprise under key support by the Conghua District, Guangzhou City, and Guangdong Province governments.
The company has always adhered to its corporate vision of 'refined research, robust manufacturing, quality medicines, and global outreach', striving to become a value creator in specialized APIs through high-quality CDMO services and core technical products.
On the R&D front, the company adheres to a technology-driven approach to value creation. In recent years, it has invested in building a quality and technology center to meet current regulations, CFDI inspections, and audits from domestic and international clients, further enhancing professional development and international collaboration efficiency. On the production front, the company has constructed multiple multifunctional API workshops, a matching wastewater treatment station, and warehouses compliant with international audit standards. This reinforces the core manufacturing capabilities driven by technology and results-oriented value realization, achieving a seamless integration from APIs to formulations in the group's product chain. On the sales front, the company leverages its existing platforms to undertake CDMO business for innovative drug APIs and generic drug APIs, steadily expanding international registration business to achieve product exports.
Guangdong Xianqiang Pharmaceutical Co., Ltd. will remain dedicated to human health, adhering to the two development strategies of 'quality CDMO services + core technical products'. It strives to provide patients with health products, employees with a career development platform, and partners with opportunities for win-win collaboration, all while working hard to strive for a bright future together!